The Indian pharmaceutical sector is witnessing a major milestone as Anthem Biosciences IPO opened for subscription on July 15, 2025, with a price band of Rs 540–570. This ₹3,395 crore public offering represents one of the largest healthcare IPOs in recent times, positioning the Bengaluru-based company as a significant player in India’s pharmaceutical landscape.
Table of Contents
Anthem Biosciences: IPO Overview and Key Details
The Rs 3,395 crore issue is entirely offer-for-sale (OFS) and will close on July 16, making it a relatively short subscription window. Anthem Biosciences IPO will be list on BSE, NSE with a tentative listing date fixed as Monday, July 21, 2025.
| Parameter | Details |
|---|---|
| Price Band | ₹540 – ₹570 per share |
| Issue Size | ₹3,395 crore |
| Lot Size | 26 shares |
| Minimum Investment | ₹14,820 (at upper price band) |
| Market Cap | ₹31,867 crore (at upper band) |
| Listing Date | July 21, 2025 |
| Allotment Date | July 17, 2025 |
Financial Performance and Valuation
Anthem has grown by 30% YoY from ₹1,483.07 Cr in FY24 to ₹1,930.29 Cr in FY25. The company’s profitability has also shown strong momentum, with PAT growth has increased to 23% YoY from ₹367.31 Cr in FY24 to ₹451.26 crore in FY25.
However, the valuation appears stretched. At the upper price band of ₹570, Anthem Biosciences is valued at around ₹31,800 crore. With a net profit of ₹451 crore in FY25, this gives the IPO a Price-to-Earnings (P/E) ratio of approximately 70.5 times.
Grey Market Premium (GMP) Analysis
The grey market sentiment reflects investor enthusiasm. Anthem Biosciences IPO GMP today is INR 95 per share, indicating a potential listing premium of approximately 16.7% at the upper price band. This suggests strong demand from retail and institutional investors.
Company Profile and Business Model
Anthem Biosciences Limited, founded in 2006, is one of the growing innovation-driven pharmaceutical companies specializing in contract research and manufacturing services (CRAMS). The company serves both domestic and international markets, focusing on:
- Contract Research Organization (CRO) services
- Contract Development and Manufacturing Organization (CDMO) operations
- Active Pharmaceutical Ingredients (API) manufacturing
- Specialty chemicals production
Investment Considerations
Strengths:
- Strong revenue growth trajectory (30% YoY)
- Diversified service portfolio in high-growth CRAMS sector
- Established international client base
- Innovation-focused business model
Concerns:
- High valuation multiple (70.5x P/E)
- Entirely OFS structure (no funds to company)
- Competitive pharmaceutical industry landscape
Market Allocation and Subscription Strategy
The retail quota is 35%, QIB is 50%, and HNI is 15%. This allocation favors institutional investors while providing adequate opportunity for retail participation.
For retail investors, the minimum investment requirement of ₹14,820 makes this IPO accessible to a broad investor base, though the high valuation warrants careful consideration.
Industry Context and Growth Prospects
The Indian pharmaceutical sector continues to benefit from global outsourcing trends, particularly in contract manufacturing and research services. Anthem’s positioning in the CRAMS space aligns with this macro trend, potentially supporting long-term growth prospects.
The company’s focus on innovation and international markets positions it well to capitalize on the growing demand for pharmaceutical outsourcing services.
For more insights on pharmaceutical sector investments and market trends, visit TechnoSports Healthcare.
As detailed in the MoneyControl analysis, investors should carefully evaluate the risk-reward profile before making investment decisions.
Stay updated with IPO analysis and investment insights at TechnoSports for comprehensive coverage of India’s capital markets.
FAQs
Q: Should retail investors apply for Anthem Biosciences IPO given the high valuation?
A: While the company shows strong growth fundamentals with 30% revenue growth and 23% profit growth, the P/E ratio of 70.5x appears stretched. Retail investors should consider their risk tolerance and investment horizon, as the high valuation may limit short-term gains despite positive GMP signals.
Q: When will Anthem Biosciences IPO shares be credited to investor accounts?
A: Share allotment is scheduled for July 17, 2025, with listing expected on July 21, 2025. Successful applicants will receive shares in their demat accounts by the allotment date, while refunds for unsuccessful applications will be processed simultaneously.
